Alzheon’s oral anti-amyloid drug has potential to be first oral Aβ-targeting therapy approved in US and EU: GlobalData Read more
CRISPR-based innovations drive $21 bn in pharma licensing deals over five years: GlobalData Read more
Pfizer’s Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028: GlobalData Read more